SAN FRANCISCO--(BUSINESS WIRE)--Pathway Therapeutics, Inc., a San Francisco based company developing novel therapeutics that target PI3K and mTOR, announced today the appointment of Mark Perry and Dr. Paul Goddard to its board of directors.
“This is the perfect time to bring both Mark and Paul onto the Pathway board. I am thrilled that at this dynamic point in our company’s evolution, with our first cancer therapeutic in the clinic, we will have two additional experienced board members to provide strategic and operational guidance to the company,” said Dr. Julie Cherrington, Pathway’s president and CEO. In late May 2011, Pathway announced that the IND for PWT33597, its balanced inhibitor of PI3K alpha and mTOR, had been accepted by the FDA; the company is now actively enrolling patients into its Phase 1 oncology trial.
